Somatic mutations that arise during cell proliferation and are then subject to positive selection are major causes of cancer and other diseases 6 . Acquired mutations are often present in just some of the cells in a sample, and can therefore be detected in next generation sequencing data from their presence at allelic fractions less than 50% 5, 7 . We reasoned that the analysis of sequencing data from hES cells might reveal previously unappreciated mosaic mutations and mutation-driven expansions acquired during hES cell culture. This approach would complement previous studies describing culturederived chromosomal-scale aneuploidies and megabase-scale copy number variants (CNVs) in hPS cells 1, 8, 9 . To this end, we collected and performed whole-exome sequencing (WES) of hES cell lines that were listed on the registry of hES cell lines maintained by the US National Institutes of Health (NIH) (Fig. 1a, b) and were able to obtain, bank and sequence 114 independent hES cell lines (Fig. 1c-e) . We selected cell lines at low to moderate passage (P) numbers (mean P18, range P3-P37) and cultured them in a common set of growth conditions for an average of 2.7 ± 0.7 (± s.d.) passages (range 2-6 passages) before banking and sequencing (Fig. 1f, g ). As hES-cell-derived differentiated cells are currently being evaluated in clinical trials for their safety and utility in a range of diseases such as macular degeneration 10
. To this end, we collected and performed whole-exome sequencing (WES) of hES cell lines that were listed on the registry of hES cell lines maintained by the US National Institutes of Health (NIH) (Fig. 1a, b) and were able to obtain, bank and sequence 114 independent hES cell lines (Fig. 1c-e) . We selected cell lines at low to moderate passage (P) numbers (mean P18, range P3-P37) and cultured them in a common set of growth conditions for an average of 2.7 ± 0.7 (± s.d.) passages (range 2-6 passages) before banking and sequencing (Fig. 1f, g ). As hES-cell-derived differentiated cells are currently being evaluated in clinical trials for their safety and utility in a range of diseases such as macular degeneration 10 , we also obtained genomic DNA from an additional 26 independent hES cell lines that had been prepared under good manufacturing practice (GMP) conditions for potential clinical use (Fig. 1a , c, e, g). We performed WES of these 140 hES cell lines from 19 institutions to a mean read depth of 79.7 ± 0.1 (± s.e.m.) (range, 57 to 115 for UM4-6 to UM78-2) (Fig. 1h) . Further details on cell line acquisition and selection are in Supplementary Table 1 and Methods. To identify acquired mutations, we analysed the sequencing reads at high-quality, high-coverage heterozygous sites across the exome. To eliminate most inherited polymorphisms from consideration, we restricted this search to variants found in only 1-2 of the cell lines sequenced and in fewer than 0.01% of the individuals sampled by the Exome Aggregation Consortium (ExAC Database) 11 . The allelic fractions at which most remaining variants were represented among the sequence reads for any one hES cell DNA sample followed a binomial distribution, reflecting statistical sampling around the 50% level expected of inherited alleles (Fig. 2a) ; at a much smaller set of sites, variant alleles were present at lower fractions (Fig. 2a, b ). We applied a statistical test to identify variants for which the observed allelic fractions were unlikely (P < 0.01 by binomial test) to have been generated by random sampling of two equally present alleles. This search identified 263 candidate mosaic variants, of which 28 were predicted to have a damaging or disruptive effect on gene function (Supplementary Table 2 ).
The only gene affected by more than one such mutation was the tumour suppressor gene TP53. We identified six TP53 mutations in five unrelated hES cell lines (Supplementary Table 3 ), including a GMPprepared cell line (MShef10) that carried two distinct TP53 variants (G245S and R248W). These six missense mutations, although rare (< 0.01%) in the general population 11 ( Fig. 2c) , mapped to the four residues most frequently disrupted in human cancer [12] [13] [14] (Fig. 2d , Supplementary Table 3) . As P53 is mutated in approximately 50% of tumours 15 , coding mutations in these four residues are associated with a substantial fraction of human cancer disease burden. Each of the six mutations involved a cytosine residue of a CpG dinucleotide and may therefore involve a highly mutable site 16 . On a crystal structure of the human P53 protein in complex with DNA, each of the mutations mapped to the DNA-binding domain of LETTER RESEARCH P53 (ref. 17) (Fig. 2e, f) . Mutations at these positions are associated with cancer and act in a dominant negative fashion to diminish P53-mediated regulation of apoptosis, cell cycle progression, and genomic stability 18 . Individuals with germ-line mutations at these residues develop Li-Fraumeni syndrome, an autosomal dominant disease with a lifetime cancer risk of nearly 100% 19 . In these patients, tumours can arise at any age and can affect most tissues, including the brain, bones, lung, skin, soft tissues, adrenal gland, colon, stomach, and blood 20 .
To independently test the hypothesis that the inactivating TP53 mutations were acquired, we developed droplet digital PCR (ddPCR) assays to count the abundance of each allele at the four TP53 mutation sites (Fig. 3a, b, Supplementary Table 4) . Analysis of genomic DNA derived from the 140 hES cell lines confirmed that all six mutations identified by WES were indeed mosaic, with allelic fractions ranging from 7-40%, suggesting their presence in 14-80% of cells in culture (Fig. 3c) . We did not identify additional cell lines carrying mutations at these positions, suggesting that such mutations were either absent or present at allelic fractions below the sensitivity of the assay (approximately 0.1%) 21 . These findings demonstrate that each of the TP53 mutations identified in hES cells was an acquired mutation and that cells with the mutation had come to represent a significant fraction of cells in affected lines.
We next asked whether the cells harbouring these TP53 mutations expanded their representation within the hES cell population across passages. We re-obtained early passage vials for hES cell lines that were mosaic for TP53 mutations (CHB11 at P22, and WA26 at P13), thawed a fresh vial of ESI035 at P36, and analysed the genomic DNA from the frozen vial and at each subsequent passage to test for changes in mutant allelic fraction. In each of the three hES cell lines, TP53 mutant alleles increased in representation over passages (Fig. 3d ) in all but one experiment, suggesting that TP53 mutations conferred a strong selective advantage (approximately 1.9-fold per passage) under routine culture conditions (Fig. 3e, Extended Data Fig. 1, Supplementary Table 5 ). To confirm that this selective advantage was conferred by TP53 mutations and not by CNVs at chr20q11.21 (refs 1-3), we analysed all 140 hES cell lines using single nucleotide polymorphism (SNP) arrays and found that none of the lines carrying TP53 mutations also carried the chr20q CNV (Supplementary Table 6 ). Our results are consistent with a model in which the routine culture of hPS cells selects for mutations that inactivate P53, resulting in the rapid clonal expansion of such mutations when they occur. Indeed, it has previously been reported that loss of P53 activity facilitates the reprogramming of somatic cells to pluripotency 22, 23 and promotes hPS cell survival and proliferation 24 , suggesting a prominent role for P53 in regulating self-renewal in hPS cells (Fig. 3e) .
To test the reproducibility of our observations and to explore the effects of P53 mutations in additional contexts, we screened for TP53 mutations in publically available RNA sequencing (RNA-seq) data from 251 hPS cell samples in 57 published studies, corresponding to 13 hES cell and 104 human induced PS cell (hiPS cell) lines (Fig. 4a-c 
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Abnormal karyotype (21) US-UK IRB differences (11) NIH registry (11) Other providers (15) Not recoverable after thaw (3) Unavailable (9) Considered NIH registry hES cell lines Results from attempt to acquire and bank NIH registry hES cell lines Fig. 2 ). When we considered both WES and RNA-seq datasets, we identified four codons that were recurrently mutated in hPS cells: R181, G245, R248, and R273. Notably, the commonly used WA09 (H9) hES cell line manifested four distinct TP53 mutations (P151S, R181H, R248Q, and R267W) in different laboratories, further demonstrating that the mutations arose during cell culture (Fig. 4h ).
Of the 15 instances of TP53 mutations observed by either WES or RNA-seq, the percentage of mutant reads suggested that 10 were mosaic and that 3 had reached fixation (allelic fraction of 50%). Surprisingly, TP53 mutations in two cell lines, WA09 (R248Q) and WIBR3 (H193R), were present in 80% ± 3% and 100% of reads, respectively (Supplementary Table 3 ). These findings were consistent with the excess allelic fraction observed during the culture of WA26 (Fig. 3d ) and suggested the presence of additional mutational mechanisms affecting mutant TP53 allelic fraction. Indeed, we observed loss of heterozygosity (LOH) of a large telomeric domain along chromosome 17 including the TP53 locus (Extended Data Fig. 3 ) that was almost complete in a gene-targeted derivative of WIBR3 ( Fig. 4i ) and was partial in WA09, consistent with the observed high fraction (80%) of mutant TP53 reads. These results suggest that follow-on LOH after an initial TP53 point mutation confers additional selective advantage.
We next determined whether TP53 mutations affect cell differentiation or affect the survival of differentiated cells. To this end, we examined studies in which there was RNA-seq data for both hES cells and their differentiated progeny. Cell lines with substantial fractions of TP53 mutant cells could readily form teratomas, gut epithelial cells 25 ( Fig. 4i ), neuroepithelial cells 26 ( Fig. 4j) , and pancreatic polyhormonal cells 27 ( Fig. 4k) . Notably, a mosaic G245C mutation in TP53 expanded in allelic fraction over the course of differentiation 27 , suggesting a continued selective advantage in differentiating mutant cells.
Together, our analyses indicate that researchers have unknowingly and routinely used hPS cells that harbour cancer-related missense mutations in TP53, sometimes accompanied by LOH. These findings have practical implications for the use of hES cells in disease modelling and transplantation medicine. The fact that we observed TP53 mutations among both hES cells and hiPS cells cultured with a wide variety of media, substrates, and passaging methods (Extended Data Fig. 4) suggests that new culture conditions should be explored to reduce the selective pressure for TP53 mutations. We also suggest regular genetic testing of hPS cells, particularly before and after stressful interventions such as gene editing or single-cell cloning that force hPS cell populations through bottlenecks (Fig. 4l, m) . Our specific findings here suggest that the P53 pathway could be an immediate focus for these genetic tests. A comprehensive ascertainment of recurrent culture-acquired Table 3) that are rare in ExAC (< 0.0001) (c). d, The four affected P53 residues are commonly mutated in human tumours. e, On a crystal structure of P53 bound to DNA, the affected residues map to the DNA binding domain and include arginine (R) residues that directly interact with DNA. f, The residues mutated in hES cells disrupt DNA binding by P53. 
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Allelic fraction of mutation (%) Allelic fraction of mutation (%) LETTER RESEARCH mutations will require the analysis of still-larger collections of stem cell lines by both exome and whole-genome sequencing. Our findings also demonstrate that sequencing can detect potentially harmful mutations in differentiated cell preparations derived from hPS cells, providing an opportunity to increase the safety of cell replacement therapies for conditions ranging from diabetes to Parkinson's disease. Clinical trials with hPS-cell-derived materials had recently been halted owing to the discovery of undisclosed mutations 28 , though such trials have since resumed. We join others 29 in suggesting that hPS cells and their derivatives be subjected to genome-wide analyses at several key steps: during initial cell line selection; as part of the characterization of a master bank of hPS cells; and as an end-stage release criterion before the transplantation of the hPS cell-derived cellular product. Importantly, although TP53 mutations recurred at detectable fractions in several cell lines, most lines (around 95%) were free of detectable TP53 mutations despite having spent extensive time in culture. Regenerative medicine remains a viable and exciting goal that is more likely to succeed as potential pitfalls, like the one we report here, are identified and addressed.
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METHODS
Data reporting.
No statistical methods were used to predetermine sample size. All cells were tested for mycoplasma and included for analysis only upon testing negative. The identity of all cell lines was confirmed by whole-exome sequencing and SNP array analysis. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. hES cell acquisition. As a source of hES cells for this study, we focused on those that had been voluntarily listed by research institutions on the registry of hES cell lines maintained by the US National Institutes of Health (NIH) (http://grants. nih.gov/stem_cells/registry/current.htm). As of 8 July 2015, a total of 307 hES cell lines were listed on this registry. Of these, we requested viable frozen stocks of the 182 lines annotated to be available for distribution and to lack known karyotypic abnorma lities or disease-causing mutations. During our effort to obtain these cell lines, we found that 45 were subject to overly restrictive material transfer agreements that precluded their use in our studies and 11 could not be readily obtained as frozen stocks owing to differences in human subjects research regulations between the US and the UK. Nine cell lines were unavailable upon request or were overly difficult to import, and three could not be cultured despite repeated attempts. Further details on the availability of cell lines can be found in Supplementary Table 1 .
The generation of hES cells used in this study was previously approved by the institutional review boards (IRBs) of all providing institutions. Use of the hES cells for sequencing at Harvard was further approved and determined not to . To minimize stress to hES cells previously cultured and frozen under diverse conditions, cell lines were thawed in the presence of 10 μ M Y-27632 (DNSK International) into two wells of a 6-well plate, one of which contained KSR-mTeSR1 on a substrate of Matrigel, and the other containing KOSR-based hES cell medium on a monolayer of irradiated MEFs. After 24 h, Y-27632 was removed and cells were fed daily with the aforementioned media in the absence of any antibiotics. All cultures were tested for the presence of mycoplasma and cultured in a humidified 37 °C tissue culture incubator in the presence of 5% CO 2 and 20% O 2 .
Colonies of cells with hES cell morphology and with a diameter of approximately 400 μ m were transferred into KSR-mTeSR1 medium containing 10 μ M Y-27632 on a substrate of Matrigel by manual picking under a dissecting microscope. Cells with differentiated morphology were removed from plates by aspiration during feeding. Once cultures consisting of cells with homogeneous pluripotent stem cell morphology had been established, they were passaged by brief (2-10 min) incubation in 0.5 mM EDTA in PBS followed by gentle trituration in KSR-mTeSR1 medium containing 10 μ M Y-27632 and re-plating. Once cultures had reached approximately 90% confluence in one well of a six-well plate, they were passaged with ETDA onto a Matrigel-coated 10 cm plate. Upon reaching approximately 90% confluence, cell lines were dissociated with EDTA as described above and banked for later use in cryoprotective medium containing 50% KSR-mTeSR1, 10 μ M Y-27632, 10% DMSO, and 40% fetal bovine serum (HyClone). A subset of hES cell lines (Supplementary Table 1 ) were passaged enzymatically with TrypLE Express (Life Technologies), expanded onto two 15 cm plates, and frozen down in 25 cryovials. Whole-exome sequencing and genotyping. Cell pellets of approximately 1-5 million cells were generated from banked cryovials of research-grade hES cell lines, or were obtained directly from institutions providing GMP-grade hES cell lines. Cell pellets were digested overnight at 50 °C in 500 μ l lysis buffer containing 100 μ g ml −1 proteinase K (Roche), 10 mM Tris (pH 8.0), 200 mM NaCl, 5% w/v SDS, 10 mM EDTA, followed by phenol:chloroform precipitation, ethanol washes, and resuspension in 10 mM Tris buffer (pH 8.0). Genomic DNA was then transferred to the Genomics Platform at the Broad Institute of MIT and Harvard for Illumina Nextera library preparation, quality control, and sequencing on the Illumina HiSeq X10 platform. Sequencing reads (150 bp, paired-end) were aligned to the hg19 reference genome using the BWA alignment program. Genotypes from WES data for the cell lines were computed using best practices from GATK software 34 compiled on 31 July 2015. Sequencing quality and coverage were analysed using Picard tool metrics. Cross sample contamination was estimated using VerifyBamID (v1.1.2) 35 , and none was detected. Data from each cell line were independently processed with the HaplotypeCaller walker and further aggregated with the CombineGVCFs and GenotypeGVCFs walkers to generate a combined variant call format (VCF) file. Genotyped sites were finally filtered using the ApplyRecalibration walker.
To determine whether lines with or without acquired TP53 mutations showed other chromosomal aberrations or smaller regional changes in copy number, additional genotyping of the 140 hES cell lines was performed using a custom high density SNP array ('Human Psych array') that contains more than half a million SNPs across the genome. CNVs larger than 500 kb were identified using the PennCNV (v1.0.0) 36 tool (http://penncnv.openbioinformatics.org). All CNVs were manually reviewed and are shown in Supplementary Table 6 . Mosaic variant analysis. To identify candidate mosaic variants, a table of heterozygous variants was generated from the VCF (Supplementary Table 2 ). To limit the frequency of false positive calls due to sequencing artefacts and PCR errors, variants were included if they had a variant read depth of at least 10, if they were either flagged as a 'PASS' site or were not reported in the Exome Aggregation Consortium (ExAC) database 11 , and if they were not located in regions of the genome with low sequence complexity, common large insertions and segmental duplications, as described by Genovese and colleagues 5 . Multiallelic sites were split, left-aligned, and normalized. The resulting list of 2.1 million 'high-quality heterozygous variants' was further refined to include sites that were covered by at least 60 unique reads and had a high confidence variant score ('PASS') as ascertained by GATK's Variant Quality Score Recalibration software (840,222 variants). To exclude common inherited variants, we selected variants present in less than 0.01% of the (ExAC) control population and restricted our analysis to only singleton or doubleton variants (9,490 variants present in 1-2 of the 140 samples). Coverage was calculated by summing reference and alternate allele counts for each variant. Allelic fraction was calculated by dividing the alternate allele count by the total read coverage (both alleles) of the site.
Although the allelic fraction of inherited heterozygous variants is expected to be 50%, reference capture bias (a tendency of hybrid selection to capture the reference allele more efficiently than alternative alleles) causes the actual expected allele fraction for SNPs and indels to be closer to 45% and 35%, respectively 5 . To account for these technical biases, we used a binomial test with a null model centred at 45% allelic fraction for inherited SNPs and 35% for inherited indels. Variants for which this binomial test was nominally significant (P < 0.01) were deemed to be candidate mosaic variants. The nominal P-value threshold of 0.01 was chosen as an inclusive threshold in order to screen sensitively for potentially mosaic variants, at the expense of also capturing false positives for which low allelic fractions represented statistical sampling fluctuations. For this reason, we considered it important to further evaluate putative mosaic variants by independent molecular methods that deeply sample alleles at the nominated sites (Fig. 3) . A more stringent computational screen based on a P-value threshold of 1 × 10
identified three of the six TP53 variants, and TP53 was also the only gene with multiple putatively mosaic variants in this screen.
We also identified all high quality heterozygous variants that passed the inclusive statistical threshold of (P < 0.01) in our binomial test and could potentially be mosaic (n = 36,396). These data are included in Supplementary Table 2 .
Variant annotation was performed using SnpEff with GRCh37.75 Ensembl gene models. Variants with moderate effect were classified as damaging by a consensus model based on seven in silico prediction algorithms 37 . Assessment of TP53 mutation frequency in cancer. We turned to the ExAC database 11 that compiles the whole-exome sequences of over 60,000 individuals to assess the frequency at which the amino acid residues we observed to be mutated in some hES cells were affected in the general population. We then consulted the COSMIC 12 (http://cancer.sanger.ac.uk/cosmic/gene/analysis?ln= TP53), ICGC 13 (https://dcc.icgc.org/), and IARC P53 (ref. 14) (http://p53.iarc.fr/ TP53SomaticMutations.aspx) databases and plotted the percentage of tumours carrying a mutation in each codon (Fig. 2d, Extended Data Fig. 2b ).
Molecular modelling of P53 protein.
To visualize the spatial location of the amino acid residues affected by TP53 mutations observed in hES cells by WES on the P53 protein, we downloaded the 1.85 Angstrom X-ray diffraction-based structure file from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (file 2AHI) and built the model protein/DNA system (chain IDs D, G, and H) to visualize the secondary structure of a P53 monomer complexed to DNA as a ribbon diagram. DNA was illustrated as a space-filling model. Water molecules were discarded when building the wild-type model and minimized in two steps using the AMBER 16 package 38 . Affected residues were indicated as space-filling model superimposed on the ribbon diagram of P53 and highlighted in blue (wildtype) or red (mutated) without consideration of how the mutations might affect the secondary or tertiary structure of the protein. Measurement of TP53 variant allele fraction by ddPCR. We assayed the allelic fraction of the four distinct TP53 mutations identified by WES (Supplementary  Table 3 ) in the 140 hES cell lines by droplet digital PCR (ddPCR). Each ddPCR analysis incorporated a custom TaqMan assay (IDT). Assays were designed with Primer3Plus and consisted of a primer pair and a 5′ fluorescently labelled probe (HEX or FAM) with 3′ quencher (Iowa Black with Zen) for either the control (reference) or mutant (alternative) base for each identified P53 variant (Supplementary Table 4 ). Genomic DNA from each hES cell line was analysed by ddPCR according to the manufacturer's protocol (BioRad). The frequency of each allele for a given sample was estimated first by Poisson correction of the endpoint fluorescence reads 21 . These corrected counts were then converted to fractional abundance estimates of the mutant allele and multiplied by two to determine the fraction of cells carrying the variant allele. Longitudinal hES cell culture and calculation of TP53 mutation expansion. To assess how the allelic fraction of TP53 mutations might change over time in culture, hES cell lines CHB11 (passage 22 or 25), WA26 (passage 13 or 15), and ESI035 (passage 36 in two separate experiments) were serially passaged in mTeSR1 media (STEMCELL Technologies) at a density of approximately 30,000 cells cm −2 in the presence of 10 μ M Y-27632 on the day of passaging. Cells were fed daily with mTeSR1 and passaged with Accutase (Innovative Cell Technologies Inc.) at approximately 90% confluence. To monitor changes in allelic fractions, genomic DNA from cells at the indicated passages were analysed by ddPCR. To calculate the relative expansion rate of mutant relative to wild-type cells, we applied the following formula:
where R 0 is defined as the ratio of (variant positive cells)/(variant negative cells) after some number of starting passages and R 1 and R 2 represent the aforementioned ratios measured on the same sample at T 1 and T 2 > T 1 passages respectively. From this equation, the estimation of variant positive cells after T passages from starting ratio R 0 can be defined as R 0 e gT . Note that this equation estimates the relative growth rate of cells carrying the variant allele with a round of passaging as unit of time, with both relative survival and growth being incorporated. These data are included in Supplementary Table 5 . For the subsequent calculation of the earliest passage at which these mutations might have become detectable, the detection thresholds (R 0 ) for WES and ddPCR was assumed to be 0.1 (10 / 100 reads) and 0.001 (1 per 1,000 droplets), respectively. RNA sequencing analysis. In order to identify TP53 mutations in hPS cells, we analysed 256 publicly available high-throughput RNA sequencing samples of hPS cells from the SRA database 39 (http://www.ncbi.nlm.nih.gov/sra). Data accession numbers for SRA (and GEO, where applicable) are provided in Supplementary  Table 7 . 5 of these 256 samples were not considered further as they were from single cells rather than cell lines. Following sequence alignment to the hg19 human reference genome with Tophat2 (ref. 40) , single nucleotides divergent from the reference genome were identified using GATK HaplotypeCaller 34 . As sufficient sequencing depth is required to deduce sequence mutation, a threshold of 25 reads per nucleotide was set. Under this criterion, 43 samples (40 hES cell lines and 3 hiPS cell lines) had a missense mutation in TP53. 10 of the 40 hES cell samples (WA09) carried two separate mutations (Supplementary Table 7 ). Upon the identification of cell lines carrying mutant reads, RNA sequencing data from studies containing differentiated samples were included for analysis. Loss of heterozygosity analysis. In order to evaluate TP53 alleles, we assessed the level of polymorphism by calculating the ratio between the minor and major alleles across chromosome 17. So as to minimize sequencing noise and errors, we included SNPs covered by more than 10 reads and that are located in the dbSNP build 142 database 41 . The resulted wig files were then plotted using Integrative Genomics Viewer (IGV) 42 (Extended Data Fig. 4) . In order to quantify the difference in polymorphism between samples, we converted the wig files to BigWig using UCSC Genome Browser utilities 43 and summed the allelic ratios between the distal part of the short arm of chromosome 17 (17p), the proximal side of this arm and the long arm of chromosome 17 (17q). The allelic ratio sum was then divided by the region's length (bp), which resulted in the proportion of SNPs, followed by one-sided Z-score test for two population proportion to compare between the chromosome 17 areas within each sample. Whereas most samples with mutations in TP53 showed a comparable, non-significant rate of polymorphic sites along the chromosome, WIBR3 samples with H193R mutations and WA09 samples with both P151S and R248Q mutations had a significantly different proportion (P < 0.001) of polymorphic sites, in the distal part of the short arm of the chromosome (first 16 × 10 6 base pairs), including the TP53 site. Unlike the three mutant WIBR3 samples, the wild-type WIBR3 sample had a normal distribution of polymorphic sites with no significant difference between the short and long arms. Data availability. Sequence data from cell lines listed on the NIH hES cell registry have been deposited in the NCBI database of Genotypes and Phenotypes (dbGaP) under accession number phys001343.v1.p1 (at https://www.ncbi.nlm.nih. gov/gap/?term= phys001343.v1.p1). Sequence data from the remaining cell lines reported in our study have been deposited at the European Genome-phenome Archive (EGA), which is hosted by the EBI and the CRG, under accession number EGAS00001002400 (at https://www.ebi.ac.uk/ega/search/site/EGAS00001002400).
